| Bid | 160.2 |
| Market Cap | 21.88B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.76 |
| PE Ratio (ttm) | -94.16 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 174.29 |
| Volume | 1,060,694 |
| Avg. Volume (20D) | 1,247,219 |
| Open | 171.76 |
| Previous Close | 169.30 |
| Day's Range | 163.42 - 171.97 |
| 52-Week Range | 59.80 - 183.00 |
| Beta | undefined |
About NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; a...
Analyst Forecast
According to 15 analyst ratings, the average rating for NTRA stock is "Buy." The 12-month stock price forecast is $158.5, which is a decrease of -4.35% from the latest price.
Next Earnings Release
Analysts project revenue of $409.91M, reflecting a 31.76% YoY growth and earnings per share of -0.5, making a -23.08% decrease YoY.
2 months ago · businesswire.com
Natera to Report its Third Quarter 2024 Results on November 12, 2024AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 20...
2 months ago · seekingalpha.com
Natera And GeneDx: Outperforming Market Powered By Precision Medicines TailwindsThe precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Hold...
